<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2. DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           250 mg taken orally twice daily with or without food. (2.1) <BR>                           Dosing interruption and/or dose reduction to 200 mg taken orally twice daily may be required based on individual safety and tolerability, then to 250 mg taken orally once daily if further reduction is necessary. (2.2)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1 Recommended Dosing <BR>                     <BR>                        The recommended dose and schedule of XALKORI is 250 mg taken orally twice daily. Continue treatment as long as the patient is deriving clinical benefit from therapy. XALKORI may be taken with or without food. Swallow capsules whole. If a dose of XALKORI is missed, make up that dose unless the next dose is due within 6 hours.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2 Dose Modification <BR>                     <BR>                        Dosing interruption and/or dose reduction may be required based on individual safety and tolerability. If dose reduction is necessary, then reduce the dose of XALKORI to 200 mg taken orally twice daily. If further dose reduction is necessary, then reduce the dosage to 250 mg taken orally once daily based on individual safety and tolerability. Dose reduction guidelines for hematologic and non-hematologic toxicities are provided in Tables 1 and 2.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t1"><BR>                           <caption>Table 1:  XALKORI Dose Modification &#8211; Hematologic Toxicities<footnote ID="table1a">Except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).</footnote><BR>                           </caption><BR>                           <col width="25%" align="left" valign="top"/><BR>                           <col width="75%" align="left" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">CTCAE<footnote ID="table1b">NCI Common Terminology Criteria for Adverse Events.</footnote> Grade</th><BR>                                 <th styleCode="Rrule">XALKORI Dosing</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Grade 3</td><BR>                                 <td styleCode="Rrule">Withhold until recovery to Grade &#8804;2, then resume at the same dose schedule </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Grade 4</td><BR>                                 <td styleCode="Rrule">Withhold until recovery to Grade &#8804;2, then resume at 200 mg twice daily<footnote ID="table1c">In case of recurrence, withhold until recovery to Grade &#8804;2, then resume at 250 mg once daily. Permanently discontinue in case of further Grade 4 recurrence.</footnote><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t2"><BR>                           <caption>Table 2: XALKORI Dose Modification &#8211; Non-Hematologic Toxicities</caption><BR>                           <col width="40%" align="left" valign="top"/><BR>                           <col width="60%" align="left" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">CTCAE Grade</th><BR>                                 <th styleCode="Rrule">XALKORI Dosing</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Grade 3 or 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation with Grade &#8804;1 total bilirubin</td><BR>                                 <td styleCode="Rrule">Withhold until recovery to Grade &#8804;1 or baseline, then resume at 200 mg twice daily<footnote ID="table2a">In case of recurrence, withhold until recovery to Grade &#8804;1, then resume at 250 mg once daily. Permanently discontinue in case of further Grade 3 or 4 recurrence.</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Grade 2, 3 or 4 ALT or AST elevation with concurrent Grade 2, 3 or 4 total bilirubin elevation (in the absence of cholestasis or hemolysis)</td><BR>                                 <td styleCode="Rrule">Permanently discontinue</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Any Grade pneumonitis<footnote ID="table2b">Not attributable to NSCLC progression, other pulmonary disease, infection, or radiation effect.</footnote><BR>                                 </td><BR>                                 <td styleCode="Rrule">Permanently discontinue</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Grade 3 QTc prolongation</td><BR>                                 <td styleCode="Rrule">Withhold until recovery to Grade &#8804;1, then resume at 200 mg twice daily<footnoteRef IDREF="table2a"/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Grade 4 QTc prolongation</td><BR>                                 <td styleCode="Rrule">Permanently discontinue</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Monitor complete blood counts including differential white blood cell counts monthly and as clinically indicated, with more frequent repeat testing if Grade 3 or 4 abnormalities are observed, or if fever or infection occurs. Monitor liver function tests monthly and as clinically indicated, with more frequent repeat testing if Grade 2, 3 or 4 abnormalities are observed.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>